Redeye leaves a comment following Lipum’s announcement of a grant from Eurostars. The granted funds will finance (50%) a project with the aim of developing a method for predicting treatment responses to Lipum’s drug candidate SOL-116. By integrating companion diagnostics, Lipum could potentially streamline clinical trials, improve SOL-116’s chances of success, and accelerate its pathway to market approval.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se